WallStreetZenWallStreetZen

Sectors & IndustriesHealthcareDrug Manufacturers - General
Best General Drug Manufacturer Stocks to Buy Now (2022)
Top general drug manufacturer stocks in 2022 ranked by overall Zen Score. See the best general drug manufacturer stocks to buy now, according to analyst forecasts for the drug manufacturers - general industry.

Industry: Drug Manufacturers - Gene...
Ticker
Company
Forecast Score
Market Cap
Price
Price Target
Upside/Downside
Consensus
Analysts
Fore. Revenue Growth
Fore. Earnings Growth
Forecast ROE
Forecast ROA
HZNP
HORIZON THERAPEUTICS PUBLIC LTD CO
$21.96B$96.91$104.257.57%Buy87.80%38.73%34.67%19.33%
PFE
PFIZER INC
$290.66B$51.78$55.256.70%Buy12-11.15%-8.99%28.30%13.42%
MRK
MERCK & CO INC
$281.05B$110.85$107.00-3.47%Strong Buy151.35%11.04%52.47%21.78%
BMY
BRISTOL MYERS SQUIBB CO
$169.84B$79.88$76.90-3.73%Buy121.42%38.94%55.45%18.45%
NVS
NOVARTIS AG
$198.45B$91.58N/AN/AHold11.37%-9.81%26.83%13.77%
SNY
SANOFI
$118.57B$46.92N/AN/AHold15.37%20.56%9.27%5.40%
AMGN
AMGEN INC
$152.37B$285.57$247.58-13.30%Hold123.10%18.70%305.86%17.54%
JNJ
JOHNSON & JOHNSON
$463.29B$177.20$179.421.25%Buy121.65%13.71%40.41%17.21%
GSK
GSK PLC
$73.75B$36.60N/AN/AHold11.12%-18.53%225.32%34.19%
LLY
ELI LILLY & CO
$353.27B$371.79$374.560.75%Strong Buy166.81%22.46%160.69%34.09%
ABBV
ABBVIE INC
$293.55B$165.99$161.58-2.65%Buy13-0.97%16.25%141.42%16.00%
BIIB
BIOGEN INC
$41.63B$289.10$306.606.05%Buy26-3.53%-6.12%19.55%10.05%
GILD
GILEAD SCIENCES INC
$112.22B$89.47$81.43-8.99%Buy14-2.93%33.12%39.86%13.43%
GRFS
GRIFOLS SA
$5.34B$7.77$13.0067.31%Hold412.07%55.59%14.09%4.05%
AZN
ASTRAZENECA PLC
$214.15B$69.17$77.0011.32%Buy33.88%98.26%22.65%8.45%
OGN
ORGANON & CO
$6.83B$26.86$30.7514.48%Buy41.19%13.13%-142.93%14.60%
TSVT
2SEVENTY BIO INC
$547.90M$14.45$31.50117.99%Strong Buy537.31%N/A-26.05%-11.88%

General Drug Manufacturer Stocks FAQ

What are the best general drug manufacturer stocks to buy right now in Dec 2022?

According to Zen Score, the 3 best general drug manufacturer stocks to buy right now are:

1. Horizon Therapeutics Public Co (NASDAQ:HZNP)


Horizon Therapeutics Public Co (NASDAQ:HZNP) is the top general drug manufacturer stock with a Zen Score of 63, which is 17 points higher than the general drug manufacturer industry average of 46. It passed 21 out of 33 due diligence checks and has strong fundamentals. Horizon Therapeutics Public Co has seen its stock lose -6.86% over the past year, underperforming other general drug manufacturer stocks by -29 percentage points.

Horizon Therapeutics Public Co has an average 1 year price target of $104.25, an upside of 7.57% from Horizon Therapeutics Public Co's current stock price of $96.91.

Horizon Therapeutics Public Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 8 analysts covering Horizon Therapeutics Public Co, 37.5% have issued a Strong Buy rating, 37.5% have issued a Buy, 25% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

2. Pfizer (NYSE:PFE)


Pfizer (NYSE:PFE) is the second best general drug manufacturer stock with a Zen Score of 62, which is 16 points higher than the general drug manufacturer industry average of 46. It passed 23 out of 38 due diligence checks and has strong fundamentals. Pfizer has seen its stock return 0.74% over the past year, underperforming other general drug manufacturer stocks by -21 percentage points.

Pfizer has an average 1 year price target of $55.25, an upside of 6.7% from Pfizer's current stock price of $51.78.

Pfizer stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Pfizer, 25% have issued a Strong Buy rating, 8.33% have issued a Buy, 66.67% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

3. Bristol Myers Squibb Co (NYSE:BMY)


Bristol Myers Squibb Co (NYSE:BMY) is the third best general drug manufacturer stock with a Zen Score of 58, which is 12 points higher than the general drug manufacturer industry average of 46. It passed 21 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 38.68% over the past year, overperforming other general drug manufacturer stocks by 16 percentage points.

Bristol Myers Squibb Co has an average 1 year price target of $76.90, a downside of -3.73% from Bristol Myers Squibb Co's current stock price of $79.88.

Bristol Myers Squibb Co stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Bristol Myers Squibb Co, 25% have issued a Strong Buy rating, 8.33% have issued a Buy, 58.33% have issued a hold, while 0% have issued a Sell rating, and 8.33% have issued a Strong Sell.

What are the general drug manufacturer stocks with highest dividends?

Out of 13 general drug manufacturer stocks that have issued dividends in the past year, the 3 general drug manufacturer stocks with the highest dividend yields are:

1. Gsk (NYSE:GSK)


Gsk (NYSE:GSK) has an annual dividend yield of 4.59%, which is 2 percentage points higher than the general drug manufacturer industry average of 2.96%. Gsk's dividend payout is not stable, having dropped more than 10% eleven times in the last 10 years. Gsk's dividend has not shown consistent growth over the last 10 years.

Gsk's dividend payout ratio of 28.6% indicates that its high dividend yield is sustainable for the long-term.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) has an annual dividend yield of 3.83%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.96%. Sanofi's dividend payout is not stable, having dropped more than 10% two times in the last 10 years. Sanofi's dividend has not shown consistent growth over the last 10 years.

Sanofi's dividend payout ratio of 67% indicates that its dividend yield is sustainable for the long-term.

3. Novartis Ag (NYSE:NVS)


Novartis Ag (NYSE:NVS) has an annual dividend yield of 3.67%, which is 1 percentage points higher than the general drug manufacturer industry average of 2.96%. Novartis Ag's dividend payout is not stable, having dropped more than 10% three times in the last 10 years. Novartis Ag's dividend has shown consistent growth over the last 10 years.

Novartis Ag's dividend payout ratio of 34.3% indicates that its dividend yield is sustainable for the long-term.

Why are general drug manufacturer stocks up?

General drug manufacturer stocks were up 0.06% in the last day, and down -0.31% over the last week. Pfizer was the among the top gainers in the drug manufacturers - general industry, gaining 3.07% yesterday.

Pfizer and BioNTech shares are trading higher after the companies received FDA Emergency Use Authorization for their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children under 5 years.

What are the most undervalued general drug manufacturer stocks?

Based on WallStreetZen's Valuation Score, the 3 most undervalued general drug manufacturer stocks right now are:

1. Grifols Sa (NASDAQ:GRFS)


Grifols Sa (NASDAQ:GRFS) is the most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Grifols Sa has a valuation score of 71, which is 36 points higher than the general drug manufacturer industry average of 35. It passed 5 out of 7 valuation due diligence checks.

Grifols Sa's stock has dropped -27.32% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -50 percentage points.

2. Sanofi (NASDAQ:SNY)


Sanofi (NASDAQ:SNY) is the second most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Sanofi has a valuation score of 71, which is 36 points higher than the general drug manufacturer industry average of 35. It passed 5 out of 7 valuation due diligence checks.

Sanofi's stock has dropped -2.23% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -24 percentage points.

3. Organon & Co (NYSE:OGN)


Organon & Co (NYSE:OGN) is the third most undervalued general drug manufacturer stock based on WallStreetZen's Valuation Score. Organon & Co has a valuation score of 57, which is 22 points higher than the general drug manufacturer industry average of 35. It passed 4 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -8.42% in the past year. It has underperformed other stocks in the general drug manufacturer industry by -31 percentage points.

Are general drug manufacturer stocks a good buy now?

52.94% of general drug manufacturer stocks rated by analysts are a buy right now. On average, analysts expect general drug manufacturer stocks to rise by 0.55% over the next year.

What is the average p/e ratio of the drug manufacturers - general industry?

The average P/E ratio of the drug manufacturers - general industry is 32.03x.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.